SocialDiabetes, a CataloniaBio & HealthTech member, has signed a deal with French medical device company Biocorp to integrate the Mallya insulin pen into its telehealth platform.
This means patients with diabetes who use this pen will be able to control their insulin doses themselves, and get personalised recommendations. The clinical data for each patient is monitored on the platform, which uses artificial intelligence and big data, for healthcare professionals to consult and follow up.
Currently, more than 250,000 patients in Spain, Mexico, Colombia and Chile use the Catalan firm platform. The deal with Biocorp will open up new international markets with the potential for an additional 850,000 patients.
Today SocialDiabetes announced new shareholders CAF (Latin American Development Bank) and ALLVP, one of the most important venture capital funds in Mexico committed to innovative companies.
Photo: María Jesús Salido and Víctor Bautista, founders of SocialDiabetes - © SocialDiabetes
You may also be interested in:
Comments